Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function [0.03%]
肾素-血管紧张素系统两类阻滞剂联合使用导致高钾血症、低血压和肾功能损伤的风险
Raquel Esteras,Maria Vanessa Perez-Gomez,Laura Rodriguez-Osorio et al.
Raquel Esteras et al.
European and United States regulatory agencies recently issued warnings against the use of dual renin-angiotensin system (RAS) blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II rec...
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress [0.03%]
抗痴呆药物：临床实践中的当前处方及在研新药
Florindo Stella,Márcia Radanovic,Paulo Renato Canineu et al.
Florindo Stella et al.
Almost three decades after the publication of the first clinical studies with tacrine, the pharmacological treatment of Alzheimer's disease (AD) remains a challenge. Randomized clinical trials have yielded evidence of significant - although...
Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs [0.03%]
安全停药：抗血小板药物停用后的血小板活性系统回顾
Isobel Ford
Isobel Ford
The platelet P2Y12 antagonists are widely used, usually in combination with aspirin, to prevent atherothrombotic events in patients with acute coronary syndromes during percutaneous coronary intervention and after placement of arterial sten...
European Union pharmacovigilance capabilities: potential for the new legislation [0.03%]
欧盟药物警戒能力：新立法的潜力
John Joseph Borg,Amy Tanti,Dimitrios Kouvelas et al.
John Joseph Borg et al.
European Directives and Regulations introduced between late 2010 and 2012 have substantially overhauled pharmacovigilance processes across the European Union (EU). In this review, the implementation of the pharmacovigilance legislative fram...
Mahyar Etminan,Hao Luo,Paul Gustafson
Mahyar Etminan
Objectives: The objective of this study was to quantify the risk of intracranial hypertension (ICH) with the intrauterine levonorgestrel (IUL) device Mirena(®). ...
Safety risks with investigational drugs: Pharmacy practices and perceptions in the veterans affairs health system [0.03%]
退伍军人医疗体系中关于 Investigational 药物的安全风险：药房实践与意识感知
Jennifer L Cruz,Jamie N Brown
Jennifer L Cruz
Objectives: Rigorous practices for safe dispensing of investigational drugs are not standardized. This investigation sought to identify error-prevention processes utilized in the provision of investigational drug services...
Nermin Bayar,Selçuk Küçükseymen,Sevil Göktaş et al.
Nermin Bayar et al.
Trastuzumab (TZ), a monoclonal antibody against human epidermal growth factor receptor type 2 (HER2), is an important biological agent used for the treatment of positive breast cancer. This paper presents a 46-year-old female patient who de...
A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone [0.03%]
扎利普隆对下次睡眠产生残留效应的CRCDS Mini-Sim灵敏度的研究——一项随机交叉双盲安慰剂对照临床试验
Arthur A Simen,Cynthia Gargano,Jang-Ho Cha et al.
Arthur A Simen et al.
Objectives: We sought to validate Cognitive Research Corporation's Driving Simulator (CRCDS Mini-Sim) for studies of drug safety with respect to driving ability. ...
Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety [0.03%]
面向公共卫生与安全的药物市场转型：滥用阻制剂技术助力疼痛管理
Kyle Simon,Stacey L Worthy,Michael C Barnes et al.
Kyle Simon et al.
This article evaluates abuse-deterrent formulations (ADFs) as a method to reduce prescription drug abuse while ensuring access to vital medications for individuals with legitimate need; assesses the pros and cons of ADFs and the current sta...
Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem [0.03%]
肺栓塞溶栓治疗的出血风险：问题范围
Mitchell J Daley,Manasa S Murthy,Evan J Peterson
Mitchell J Daley
Acute pulmonary embolism represents a major complication of venous thromboembolism that is associated with high morbidity and mortality. Guidelines recommend the rapid initiation of anticoagulation and consideration of thrombolytic therapy ...